Examkin

Patient Management

2074 questions

All types2,074Multiple choice1,048Multiple select393Matching221Ordering412
Question 1401Question →

A 58-year-old woman is evaluated in the intensive care unit for a rapidly declining platelet count. She was admitted 6 days ago for severe pneumonia and started on broad-spectrum antibiotics and prophylactic subcutaneous unfractionated heparin. Her platelet count on admission was 250,000/μL250,000/\mu L and is now 55,000/μL55,000/\mu L. She has no active bleeding, but a lower extremity ultrasound reveals a new deep vein thrombosis in the right femoral vein. The clinical team diagnoses highly probable heparin-induced thrombocytopenia (HIT) with thrombosis. Arrange the following steps regarding the ongoing monitoring and transition of pharmacotherapy for this patient in the most appropriate chronological sequence.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence begins with immediately stopping all heparin products, followed by initiating a non-heparin parenteral anticoagulant, monitoring platelets until they recover to at least 150,000/μL150,000/\mu L, initiating warfarin overlap, and finally discontinuing the parenteral anticoagulant once the INR is therapeutic for 48 hours.
The management of Heparin-Induced Thrombocytopenia (HIT) follows a strict, highly tested sequence. First, the inciting agent (all heparin products) must be immediately withdrawn to stop the underlying pathophysiology. Second, because HIT is profoundly prothrombotic (as evidenced by this patient's new deep vein thrombosis), immediate alternative parenteral anticoagulation (e.g., argatroban, bivalirudin, or fondaparinux) is required. Third, the clinician must monitor the patient's platelet count daily; this serves as the primary metric for treatment evaluation. Fourth, only after the platelet count has recovered to normal levels (≥150,000/μL\ge 150,000/\mu L) is it safe to initiate warfarin. Finally, standard bridging rules apply: the parenteral agent must be continued for at least 5 days AND until the INR is therapeutic (2.0-3.0) for at least 48 hours before it can be safely discontinued.

Step-by-Step Solution

1
Stop all heparin exposure.
Halts the formation of heparin-PF4-antibody complexes.
Continued exposure to even minimal amounts of heparin (like flushes) perpetuates the prothrombotic state.
2
Start a non-heparin parenteral anticoagulant (e.g., argatroban).
Provides immediate anticoagulation to treat the existing deep vein thrombosis.
Patients with HIT have an extremely high risk of progressive or new thrombosis, necessitating immediate alternative anticoagulation.
3
Monitor platelet count daily.
Identifies the resolution of the acute HIT phase once platelets reach ≥150,000/μL\ge 150,000/\mu L.
Platelet recovery indicates that the profound hypercoagulable state is subsiding, marking the safe window for transition to oral therapy.
4
Initiate oral warfarin therapy while continuing the parenteral anticoagulant.
Begins the transition to long-term outpatient anticoagulation.
Warfarin must be delayed until platelet recovery to avoid the rapid depletion of Protein C, which can paradoxically worsen thrombosis.
5
Discontinue the parenteral anticoagulant after 48 hours of a therapeutic INR.
Completes the transition to monotherapy with warfarin.
Bridging ensures that warfarin has achieved its full antithrombotic effect (depletion of prothrombin/Factor II) before the rapid-acting agent is removed.

Key Concept

Monitoring and Treatment Evaluation in Heparin-Induced Thrombocytopenia (HIT)
Estimated Time:1m 30s
Question 1402Question →

A 72-year-old man with a 6-year history of Parkinson disease is brought to the neurology clinic by his wife due to new-onset visual hallucinations over the past two weeks. He reports seeing unfamiliar people standing in his living room, which is causing him significant distress. His motor symptoms (tremor and bradykinesia) have been well-controlled recently. His current daily medication regimen includes carbidopa-levodopa, pramipexole, amantadine, and trihexyphenidyl. Vital signs are within normal limits. Neurologic examination shows mild resting tremor and rigidity, unchanged from his previous visit. Laboratory studies, including a urinalysis and basic metabolic panel, are unremarkable.

According to the standard step-wise approach for managing Parkinson disease-related psychosis, arrange the following pharmacologic modifications in the correct sequential order (from the first step to the final step).

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequential order is to first discontinue trihexyphenidyl, then discontinue amantadine, then discontinue pramipexole, and finally initiate quetiapine if symptoms persist.
The management of Parkinson disease psychosis involves a step-wise approach to minimize medication-induced delirium while attempting to preserve motor function. The first step is always to rule out general medical conditions (e.g., infections). Once ruled out, a sequential reduction of adjunctive Parkinson medications is performed in reverse order of their motor efficacy and forward order of their side effect profile. Anticholinergics (trihexyphenidyl) are the most deliriogenic and provide the least motor benefit, making them the first to be discontinued. If symptoms persist, amantadine is discontinued next. This is followed by MAO-B inhibitors (if present) and then dopamine agonists (pramipexole). Only if psychosis persists despite the withdrawal of these adjunctive therapies (or if severe motor deterioration prevents their withdrawal) should an atypical antipsychotic with low extrapyramidal risk, such as quetiapine or pimavanserin, be initiated.

Step-by-Step Solution

1
Identify the primary clinical problem
The patient is experiencing new-onset visual hallucinations (psychosis) induced by Parkinson disease medications, with secondary causes (e.g., infection, metabolic derangements) already ruled out.
Visual hallucinations are a common adverse effect of dopaminergic and anticholinergic therapies in advanced Parkinson disease and must be managed systematically.
2
Determine the first step in the medication taper protocol
Discontinue the anticholinergic agent (trihexyphenidyl).
Anticholinergics carry the highest risk for cognitive impairment and hallucinations with the least motor benefit, making them the absolute first target for discontinuation.
3
Determine the next sequential medications to withdraw if symptoms persist
Discontinue amantadine, followed by the dopamine agonist (pramipexole).
Amantadine has high neuropsychiatric toxicity and should be removed next. Dopamine agonists are tapered after amantadine because they provide greater motor control, even though they frequently trigger psychosis.
4
Determine the final intervention for refractory psychosis
Initiate an atypical antipsychotic (quetiapine).
If psychosis persists despite discontinuing adjunctive therapies, a low-potency atypical antipsychotic without significant D2 antagonism is added to avoid worsening motor symptoms.

Key Concept

The step-wise pharmacologic management of Parkinson disease psychosis involves sequentially discontinuing adjunctive medications in reverse order of motor efficacy (anticholinergics, then amantadine, then MAO-B inhibitors, then dopamine agonists) before initiating an atypical antipsychotic.
Question 1403Question →

A 68-year-old man is evaluated in the outpatient clinic for a 1-day history of severe right great toe pain, swelling, and redness. He reports the pain woke him from sleep and is so exquisite that he cannot bear the weight of a bedsheet on his foot. Medical history is notable for hypertension, type 2 diabetes mellitus, and chronic kidney disease stage 3b. One week ago, he was diagnosed with a peptic ulcer associated with Helicobacter pylori and was started on a 14-day eradication regimen. Current medications include lisinopril, amlodipine, clarithromycin, amoxicillin, and omeprazole. Vital signs are temperature 37.3°C (99.1°F), blood pressure 138/82 mmHg, and pulse 88/min. Physical examination shows a swollen, erythematous, and exquisitely tender right first metatarsophalangeal joint. Arthrocentesis is performed, and synovial fluid analysis reveals a leukocyte count of 25,000/mm³ and negatively birefringent, needle-shaped crystals. Gram stain is negative. Laboratory studies show:

TestResult
Leukocyte count11,200/mm³
Serum uric acid5.4 mg/dL
Serum creatinine1.7 mg/dL (baseline 1.6 mg/dL)

Which of the following is the most appropriate next step in pharmacologic management for this patient?

Show answer & explanation

Answer: Intra-articular triamcinolone

Answer

Intra-articular triamcinolone is the most appropriate pharmacologic intervention.
The patient is experiencing an acute gout flare, definitively diagnosed by the presence of negatively birefringent monosodium urate crystals in the synovial fluid. Standard first-line systemic therapies for acute gout include nonsteroidal anti-inflammatory drugs (NSAIDs) and colchicine. However, in this patient, NSAIDs (e.g., indomethacin) are contraindicated due to his underlying chronic kidney disease and concurrent use of an angiotensin-converting enzyme (ACE) inhibitor (lisinopril), a combination that carries a high risk of precipitating acute renal failure. Colchicine is also strictly contraindicated because the patient is taking clarithromycin for Helicobacter pylori eradication. Clarithromycin is a potent inhibitor of both cytochrome P450 3A4 (CYP3A4) and P-glycoprotein; coadministration with colchicine can lead to fatal colchicine toxicity (neuromyopathy, cytopenias), particularly in patients with baseline renal impairment. Therefore, a localized intra-articular glucocorticoid injection (e.g., triamcinolone) is the safest and most effective targeted intervention. It provides rapid local symptom relief for monoarticular gout while completely bypassing the risks of systemic drug-drug interactions and nephrotoxicity.

Step-by-Step Solution

1
Analyze the synovial fluid and laboratory results.
Negatively birefringent crystals definitively confirm an acute gout flare, ruling out septic arthritis despite the normal serum uric acid level.
Establishing the correct diagnosis is the necessary first step before selecting pharmacotherapy.
2
Evaluate the safety of NSAIDs for this specific patient.
Indomethacin is contraindicated.
The patient has chronic kidney disease and is taking an ACE inhibitor; NSAIDs can precipitate severe acute renal failure in this setting.
3
Evaluate the safety of colchicine for this specific patient.
Colchicine is contraindicated.
The patient is taking clarithromycin, a strong CYP3A4 and P-glycoprotein inhibitor, which would cause fatal colchicine toxicity.
4
Select the optimal alternative therapy.
Intra-articular triamcinolone is chosen.
Localized glucocorticoid injection provides rapid anti-inflammatory relief for monoarticular gout without systemic drug interactions or nephrotoxicity.

Key Concept

Pharmacologic management of acute gout in patients with complex comorbidities and critical drug-drug interactions.
Question 1404Question →

A 62-year-old man with a 12-year history of type 2 diabetes mellitus and chronic kidney disease is evaluated during a routine follow-up visit. One month ago, his hemoglobin A1c was 8.1% and his estimated glomerular filtration rate (eGFR) was 45 mL/min/1.73 m 2^2. At that time, dapagliflozin was added to his medication regimen, which also includes metformin and lisinopril, to optimize glycemic control and slow the progression of diabetic nephropathy. Today, the patient reports feeling well overall. He denies urinary frequency, dysuria, dizziness, or orthopnea. He mentions having mild, intermittent bilateral knee pain due to osteoarthritis and asks for a medication recommendation. His blood pressure is 126/78 mm Hg and heart rate is 74/min.

Laboratory studies obtained today show:

TestResult
Serum sodium138 mEq/L
Serum potassium4.6 mEq/L
Serum urea nitrogen24 mg/dL
Serum creatinine1.8 mg/dL (Baseline 1.5 mg/dL)
eGFR37 mL/min/1.73 m2^2

Which of the following is the most appropriate next step in the management of this patient?

Show answer & explanation

Answer: Continue the current regimen and recommend oral acetaminophen for the knee pain

Answer

The most appropriate next step is to continue the current medication regimen without modifications and recommend oral acetaminophen for the patient's knee osteoarthritis pain.
The correct answer is to continue the current regimen and recommend oral acetaminophen for the knee pain. This patient has experienced a 20% increase in serum creatinine (from 1.5 mg/dL to 1.8 mg/dL) one month after initiating dapagliflozin, an SGLT2 inhibitor. SGLT2 inhibitors cause afferent arteriolar vasoconstriction by increasing sodium delivery to the macula densa, which lowers intraglomerular pressure. This hemodynamic change is the mechanism behind their long-term renoprotective effect, but it causes an expected, mild initial drop in eGFR. Current clinical guidelines state that an initial serum creatinine increase of up to 30% from baseline is acceptable and should not prompt discontinuation of the drug. Furthermore, the patient's osteoarthritis should be managed with acetaminophen. Oral NSAIDs (like naproxen) are contraindicated in patients with chronic kidney disease, as they inhibit prostaglandin-mediated afferent arteriolar vasodilation, increasing the risk of severe acute kidney injury, particularly in patients taking ACE inhibitors.

Step-by-Step Solution

1
Analyze the patient's change in renal function after initiating the SGLT2 inhibitor.
The serum creatinine increased from 1.5 mg/dL to 1.8 mg/dL, representing exactly a 20% increase.
To determine if the laboratory change falls within the acceptable safety threshold for this class of medications.
2
Evaluate the clinical guidelines for SGLT2 inhibitor monitoring.
An initial increase in serum creatinine of up to 30% is an expected, hemodynamically mediated effect that correlates with long-term renoprotection. The medication should be continued.
To make the correct evidence-based clinical decision regarding the continuation or discontinuation of the new medication.
3
Assess the patient's request for osteoarthritis pain medication in the context of his comorbidities.
The patient has chronic kidney disease and is taking an ACE inhibitor. NSAIDs are contraindicated due to the risk of precipitating acute kidney injury.
To select an analgesic (acetaminophen) that provides safe symptom management without exacerbating renal impairment.

Key Concept

An initial increase in serum creatinine of up to 30% is an expected hemodynamic effect of SGLT2 inhibitors and does not warrant discontinuation. Oral NSAIDs are contraindicated in patients with CKD taking ACE inhibitors.
Question 1405Question →

A 45-year-old man is evaluated in the hospital prior to discharge. He was admitted three days ago for acute dyspnea and was found to have a new-onset nonischemic cardiomyopathy with a left ventricular ejection fraction of 20%. He has been treated with intravenous furosemide and is now breathing comfortably on room air. He has no orthopnea, and his volume status is clinically optimized. Medical history is notable for hypertension and an episode of severe lip swelling and airway compromise requiring epinephrine after taking lisinopril two years ago. Current vital signs are blood pressure 118/75 mmHg, heart rate 72/min, and respirations 14/min.

Laboratory results obtained this morning are as follows:

TestResultReference Range
Sodium138 mEq/L136-145 mEq/L
Potassium5.8 mEq/L3.5-5.0 mEq/L
Chloride102 mEq/L98-106 mEq/L
Bicarbonate24 mEq/L22-28 mEq/L
Blood urea nitrogen22 mg/dL8-23 mg/dL
Creatinine1.3 mg/dL0.7-1.3 mg/dL

Which of the following pharmacologic interventions are appropriate to initiate prior to discharge? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: Metoprolol succinate; Dapagliflozin; Isosorbide dinitrate and hydralazine

Answer

The appropriate interventions to initiate are metoprolol succinate, dapagliflozin, and the combination of isosorbide dinitrate and hydralazine.
This patient requires initiation of guideline-directed medical therapy for newly diagnosed heart failure with reduced ejection fraction (HFrEF). Standard quad-therapy components generally include an ARNI/ACEi/ARB, an evidence-based beta-blocker, a mineralocorticoid receptor antagonist (MRA), and an SGLT2 inhibitor. Metoprolol succinate is an evidence-based beta-blocker that should be started in stable, euvolemic patients. Dapagliflozin reduces mortality and hospitalizations in HFrEF regardless of diabetes status and is safe given the patient's adequate renal function. Because the patient has a history of ACE-inhibitor-induced angioedema, all ACE inhibitors, ARBs, and ARNIs (e.g., sacubitril-valsartan) are strictly contraindicated. In patients who cannot tolerate these agents, the combination of isosorbide dinitrate and hydralazine is the recommended alternative to provide mortality-reducing afterload and preload reduction.

Step-by-Step Solution

1
Assess the clinical state and primary diagnosis.
The patient has newly diagnosed heart failure with reduced ejection fraction (HFrEF) with an ejection fraction of 20%, and is now euvolemic and hemodynamically stable.
Establishing baseline stability is required before safely initiating guideline-directed medical therapy (GDMT) prior to discharge.
2
Review the patient's medical history for contraindications to standard GDMT.
The patient has a history of life-threatening angioedema secondary to lisinopril.
A history of ACE-inhibitor-induced angioedema acts as an absolute contraindication to all ACE inhibitors, ARBs, and ARNIs (e.g., sacubitril-valsartan) due to cross-reactivity and bradykinin accumulation.
3
Evaluate the current laboratory values, specifically electrolytes and renal function.
The patient's serum potassium is significantly elevated at 5.8 mEq/L.
Hyperkalemia is an absolute contraindication to initiating mineralocorticoid receptor antagonists (MRAs) such as spironolactone, which would further increase potassium levels.
4
Select the appropriate, safe pharmacological agents to form a modified GDMT regimen.
Metoprolol succinate, dapagliflozin, and the combination of isosorbide dinitrate and hydralazine are selected.
Beta-blockers and SGLT2 inhibitors remain safe and indicated. Hydralazine and nitrates serve as the evidence-based alternative for mortality reduction in HFrEF when renin-angiotensin-aldosterone system inhibitors are contraindicated.

Key Concept

Initiation of guideline-directed medical therapy for HFrEF requires careful adjustment for absolute contraindications, specifically avoiding ARNIs/ACEis/ARBs in patients with prior angioedema and avoiding MRAs in patients with significant hyperkalemia.
Question 1406Question →

A 71-year-old man presents to the outpatient clinic for a follow-up appointment four weeks following a hospitalization for new-onset atrial fibrillation. While admitted, oral amiodarone was initiated for maintenance of sinus rhythm. The patient reports feeling well with no palpitations, dyspnea, or chest pain. His current medications include amiodarone, lisinopril, and atorvastatin. Today's electrocardiogram demonstrates normal sinus rhythm with a heart rate of 68/min and a QTc interval of 430 ms. The physician counsels the patient on the necessity of longitudinal follow-up to detect potential medication-induced toxicities. Which of the following evaluations are required as part of routine periodic monitoring for this patient's antiarrhythmic therapy? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: Serum thyroid-stimulating hormone level; Serum alanine aminotransferase level; Electrocardiogram

Answer

The necessary routine monitoring parameters for a patient on long-term amiodarone therapy include a serum thyroid-stimulating hormone level, a serum alanine aminotransferase level, and an electrocardiogram.
Amiodarone is a highly effective antiarrhythmic agent but carries a significant risk of multiorgan toxicity. Routine periodic monitoring is strictly required to detect insidious adverse effects early. Its high iodine content and direct cytotoxic effects can cause both hypothyroidism and hyperthyroidism, necessitating regular monitoring of serum thyroid-stimulating hormone. It can also cause asymptomatic hepatotoxicity, making periodic assessment of serum alanine aminotransferase essential. Finally, as a class III antiarrhythmic, amiodarone prolongs the action potential and can cause dangerous QTc prolongation or bradycardia, requiring routine electrocardiographic surveillance.

Step-by-Step Solution

1
Identify the primary medication and its multiorgan toxicity profile.
The patient is taking amiodarone, a class III antiarrhythmic known to cause thyroid, hepatic, pulmonary, and cardiac toxicities.
Understanding the unique adverse effects of a high-risk pharmacotherapy is required to establish the correct surveillance strategy.
2
Determine the guideline-concordant routine screening tests for amiodarone.
Routine periodic monitoring mandates a serum TSH, liver function tests (including ALT), and an electrocardiogram.
These specific tests detect the most common and dangerous insidious toxicities of amiodarone before they become clinically severe.
3
Evaluate the remaining options against appropriate utilization standards.
High-resolution computed tomography of the chest and routine serum creatine kinase levels are excluded.
Routine HRCT is an overutilization of advanced imaging when a standard chest radiograph suffices. Routine CK monitoring is inappropriate for asymptomatic patients on statins, despite the presence of a CYP3A4 interaction with amiodarone.

Key Concept

Patients receiving long-term amiodarone therapy require routine periodic monitoring of thyroid function (TSH), liver function (AST/ALT), and cardiac conduction (ECG) to detect potentially severe adverse effects.
Question 1407Question →

A 2929-year-old woman presents to the clinic for her first prenatal visit. She is currently at 66 weeks of gestation based on her last menstrual period. The patient has a 44-year history of Hashimoto thyroiditis and has been well-controlled on levothyroxine 100100 mcg daily for the past two years. She reports no symptoms of fatigue, cold intolerance, constipation, or weight changes. Her most recent serum thyroid-stimulating hormone (TSH) level obtained 33 months ago was 1.61.6 μ\mu U/mL (reference range: 0.4−4.00.4-4.0 μ\mu U/mL). A home pregnancy test was positive one week ago, and a serum human chorionic gonadotropin level drawn yesterday confirms the pregnancy. Vital signs and physical examination today are unremarkable. Which of the following is the most appropriate next step in the monitoring and management of this patient's thyroid disease?

Show answer & explanation

Answer: Increase the levothyroxine dosage by approximately 30%30\% today and assess serum TSH levels in 44 weeks.

Answer

Increase the levothyroxine dosage by approximately 30%30\% today and assess serum TSH levels in 44 weeks.
Pregnancy induces a significant increase in maternal estrogen production, which subsequently stimulates the hepatic synthesis of thyroxine-binding globulin (TBG). This increase in TBG binds more circulating thyroxine, decreasing the fraction of free, biologically active thyroid hormones. Furthermore, the developing fetus is entirely dependent on maternal thyroxine during the first trimester for normal neurodevelopment. To maintain a euthyroid state, patients with pre-existing primary hypothyroidism require an empiric levothyroxine dose increase of approximately 30%30\% (often achieved by having the patient take two additional baseline doses per week) immediately upon the confirmation of pregnancy. Because it takes several weeks for the hypothalamic-pituitary axis to equilibrate following a dose change, the most appropriate monitoring strategy is to assess serum TSH levels in 44 weeks, and then every 44 weeks during the first half of the pregnancy.

Step-by-Step Solution

1
Identify the patient's current physiologic state and underlying medical conditions.
The patient is newly pregnant (66 weeks gestation) and has pre-existing Hashimoto thyroiditis treated with levothyroxine.
Pregnancy significantly alters endocrine physiology and pharmacokinetics, requiring immediate treatment evaluation.
2
Recall the physiologic changes in thyroid hormone transport during pregnancy.
Elevated estrogen levels increase hepatic synthesis of thyroxine-binding globulin (TBG), which binds more circulating thyroxine and lowers the free (active) hormone fraction.
Understanding this mechanism explains why patients without endogenous thyroid function cannot meet the newly increased metabolic demands.
3
Determine the required treatment modification.
An immediate, empiric increase in the levothyroxine dosage by approximately 30%30\% (often achieved by adding two extra daily doses per week) is required.
This empiric increase is necessary to maintain a euthyroid state and ensure adequate transplacental thyroxine transfer for fetal neurodevelopment.
4
Establish the appropriate monitoring parameter and interval.
Serum TSH should be measured in 44 weeks.
It takes several weeks for TSH to equilibrate following a dose change. Monitoring should continue every 44 weeks during the first half of pregnancy.

Key Concept

In pregnant patients with pre-existing primary hypothyroidism, the levothyroxine dose should be empirically increased by approximately 30%30\% immediately upon confirmation of pregnancy, followed by TSH monitoring every 44 weeks during the first half of gestation.
Estimated Time:1m 15s
Question 1408Question →

A 32-year-old man is brought to the emergency department by ambulance due to a generalized tonic-clonic seizure. His partner reports that the abnormal movements started 20 minutes ago and have been continuous without any periods of responsiveness. He has no known medical history. Initial vital signs include a blood pressure of 145/85 mm Hg, heart rate of 118/min, and oxygen saturation of 94% on room air. No medications were administered en route. Two large-bore peripheral intravenous lines are immediately established in the resuscitation bay. Arrange the following pharmacologic interventions in the evidence-based sequence for the escalating management of status epilepticus, from initial abortive therapy to the treatment of super-refractory cases.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence for the pharmacologic escalation in status epilepticus is: 1) Intravenous lorazepam, 2) Intravenous fosphenytoin, 3) Intravenous propofol infusion, 4) Intravenous pentobarbital infusion.
The American Epilepsy Society treatment algorithm for status epilepticus involves a strict step-wise escalation. Phase 1 (0-10 minutes) requires a rapid-acting benzodiazepine such as intravenous lorazepam to abort the seizure. Phase 2 (10-30 minutes) utilizes a non-anesthetic antiepileptic drug such as intravenous fosphenytoin to achieve sustained control and prevent recurrence. Phase 3 (30-60 minutes) addresses refractory status epilepticus using continuous infusions of general anesthetics like propofol or midazolam. Finally, Phase 4 addresses super-refractory status epilepticus (seizures persisting >24 hours despite anesthetics) with deep barbiturate coma using agents like pentobarbital.

Step-by-Step Solution

1
Identify the patient's presentation as generalized convulsive status epilepticus.
The patient has had continuous seizures for 20 minutes, which meets the criteria for status epilepticus (continuous seizure >5 minutes), requiring immediate protocolized pharmacological escalation.
Prompt recognition is essential to initiate the correct time-dependent treatment algorithm and prevent permanent neuronal injury.
2
Determine the first-line (Phase 1) abortive therapy.
Intravenous lorazepam is the initial drug of choice.
Benzodiazepines enhance GABA-A receptor inhibition and are the most effective agents for rapidly terminating ongoing seizure activity.
3
Determine the second-line (Phase 2) stabilization therapy.
Intravenous fosphenytoin is administered next.
If seizures continue after adequate doses of benzodiazepines, a long-acting non-anesthetic antiepileptic drug is required to establish sustained seizure control.
4
Determine the third-line (Phase 3) therapy for refractory status epilepticus.
Continuous intravenous propofol infusion is the next appropriate step.
When seizures are refractory to Phase 1 and 2 agents, continuous anesthetic infusions are necessary to suppress cortical activity, often requiring intubation for airway protection.
5
Determine the final escalation step for super-refractory status epilepticus.
Continuous intravenous pentobarbital infusion is the last resort.
Pentobarbital induces profound burst suppression and is reserved for cases that fail to respond to other anesthetic infusions due to its significant risk of hemodynamic instability and immunosuppression.

Key Concept

The step-wise pharmacologic management of status epilepticus progresses sequentially through initial benzodiazepines, long-acting non-anesthetic antiepileptic drugs, continuous anesthetic infusions, and finally barbiturate coma for super-refractory cases.
Estimated Time:1m 30s
Question 1409Question →

An internal medicine physician is called to the bedside of a 24-year-old male patient who is receiving care in the critical care unit for diabetic ketoacidosis. The patient was admitted 14 hours prior and has been treated with continuous intravenous fluids, a regular insulin infusion, and an electrolyte protocol. The nursing staff reports that his vital signs are stable, and he is now awake, conversational, and asking for a meal.

Recent laboratory studies demonstrate:
Laboratory TestResult
Sodium140 mEq/L
Potassium4.4 mEq/L
Chloride108 mEq/L
Bicarbonate22 mEq/L
Blood glucose165 mg/dL

The clinical team determines the patient is ready to transition to a subcutaneous insulin regimen. Arrange the following steps for transitioning therapies and monitoring in the most appropriate chronological sequence.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence is to first verify resolution of ketoacidosis (closed anion gap and ability to eat), then administer subcutaneous insulin, maintain the intravenous insulin drip for a 1-to-2-hour overlap period, discontinue the intravenous drip, and finally implement routine point-of-care glucose monitoring.
The safe transition from intravenous to subcutaneous insulin in a patient with diabetic ketoacidosis (DKA) requires a precise sequence to prevent rebound ketoacidosis. First, DKA resolution must be confirmed by documenting a closed anion gap (12 mEq/L or less), blood glucose < 200 mg/dL, and the patient's ability to tolerate oral intake. Once confirmed, subcutaneous insulin must be administered. Because subcutaneous insulin requires 1 to 2 hours to reach systemic therapeutic levels, the intravenous insulin infusion must be maintained during this overlap window. Discontinuing the intravenous insulin prematurely creates a gap in insulin coverage, which leads to rapid lipolysis, ketogenesis, and relapse of DKA. After the 1-to-2-hour overlap, the intravenous drip is stopped, and routine point-of-care glucose monitoring begins to evaluate the efficacy of the new subcutaneous regimen.

Step-by-Step Solution

1
Assess the patient's clinical status and calculate the anion gap from the provided laboratory results.
The anion gap is 10 mEq/L (140 - [108 + 22]), and the patient is asking for a meal. Both criteria for diabetic ketoacidosis resolution are met.
Transitioning to subcutaneous insulin requires full resolution of ketoacidosis to prevent an immediate relapse.
2
Initiate the subcutaneous insulin regimen while the intravenous infusion continues.
Subcutaneous basal and prandial insulin are administered as the second step.
Subcutaneous insulin has a delayed onset of action and requires time to reach therapeutic serum levels.
3
Continue the intravenous insulin infusion for a mandatory overlap period.
The intravenous insulin is maintained for 1 to 2 hours after the subcutaneous injection.
This overlap provides continuous insulin coverage while the subcutaneous depot is absorbed, preventing rebound ketogenesis.
4
Stop the intravenous insulin infusion and establish ongoing surveillance.
The intravenous drip is discontinued, and point-of-care glucose testing is ordered.
Once the subcutaneous insulin is active, the intravenous route is no longer needed, and routine monitoring is required to adjust future doses.

Key Concept

Transitioning from intravenous to subcutaneous insulin in diabetic ketoacidosis requires confirming anion gap closure and maintaining a 1-to-2-hour overlap of intravenous insulin after administering the subcutaneous dose to prevent rebound acidosis.
Question 1410Question →

During a routine follow-up visit, a 62-year-old male patient reports a two-week history of bilateral thigh and shoulder pain accompanied by mild weakness. His medical history is significant for a myocardial infarction 6 months prior, and his current daily medication regimen includes aspirin, metoprolol, lisinopril, and atorvastatin 80 mg. Vital signs are within normal limits. On physical examination, there is noticeable tenderness upon palpation of the quadriceps and deltoid muscles bilaterally, and proximal muscle strength is graded at 4/5.

Laboratory studies are obtained and reveal the following:

ParameterPatient ValueReference Range
Serum creatinine1.1 mg/dL0.6-1.2 mg/dL
Creatine kinase1,850 U/L40-250 U/L
Thyroid-stimulating hormone2.5 mU/L0.5-5.0 mU/L
UrinalysisNegative for blood and proteinNegative

Which of the following is the most appropriate next step in the management of this patient?

Show answer & explanation

Answer: Discontinue atorvastatin and reassess the patient in 2 to 4 weeks

Answer

The correct answer is to discontinue the statin therapy and re-evaluate the patient's symptoms and laboratory values in 2 to 4 weeks.
The correct action is to discontinue the statin and reassess the patient in 2 to 4 weeks. Statin-induced myopathy is a known adverse effect characterized by muscle pain, tenderness, or weakness accompanied by an elevated creatine kinase (CK) level. When a patient develops intolerable muscle symptoms or has a CK level greater than 4 times the upper limit of normal (as seen in this patient with a CK of 1,850 U/L), the statin should be stopped promptly. Continuing the medication risks progression to severe rhabdomyolysis and acute kidney injury. Once the patient's symptoms resolve and the CK normalizes, it is appropriate to rechallenge the patient with a different statin or a lower dose, as lipid-lowering therapy remains crucial for secondary prevention after a myocardial infarction.

Step-by-Step Solution

1
Analyze the patient's clinical presentation.
The patient has new-onset proximal muscle pain and weakness starting months after initiating high-intensity statin therapy.
Identifying the timeline of medication initiation versus symptom onset is essential for establishing a pharmacological etiology.
2
Interpret the laboratory findings.
The creatine kinase (CK) is significantly elevated (1,850 U/L), which is greater than 7 times the upper limit of normal. Serum creatinine is normal, and urinalysis is negative for myoglobin.
This confirms a diagnosis of statin-induced myopathy and distinguishes it from severe, life-threatening rhabdomyolysis.
3
Determine the appropriate intervention.
The offending agent (atorvastatin) must be discontinued immediately to prevent progression to severe muscle damage.
For CK elevations >4 times the upper limit of normal accompanied by symptoms, cessation of the statin is the standard of care.

Key Concept

Management of statin-induced myopathy requires prompt discontinuation of the offending agent when symptoms are accompanied by a creatine kinase level greater than 4 times the upper limit of normal.
Estimated Time:1m 30s
Question 1411Question →

A 68-year-old man is evaluated in the hospital prior to discharge. He was admitted five days ago for acute decompensated heart failure. Echocardiography performed during the admission showed a left ventricular ejection fraction of 30%. His volume status was optimized with intravenous furosemide. He is now clinically stable and transitioned to an oral regimen consisting of furosemide, carvedilol, dapagliflozin, lisinopril, and spironolactone. He has an appointment to be seen in the outpatient clinic in one week. Which of the following laboratory parameters are most critical to measure at his upcoming clinic visit to monitor for potentially life-threatening adverse effects of his updated medication regimen? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: Serum creatinine; Serum potassium

Answer

The most critical laboratory parameters to monitor are serum potassium and serum creatinine.
The combination of an ACE inhibitor (lisinopril) and a mineralocorticoid receptor antagonist (spironolactone) places this patient at a high risk for hyperkalemia and acute kidney injury. ACE inhibitors decrease the production of angiotensin II and aldosterone, while spironolactone competitively blocks the aldosterone receptor in the distal tubule. Both mechanisms reduce potassium excretion into the urine. Furthermore, ACE inhibitors cause efferent arteriolar vasodilation, which reduces glomerular filtration pressure and can lead to an acute rise in serum creatinine, particularly in the setting of concurrent diuretic use. Clinical guidelines mandate checking serum potassium and serum creatinine within 1 to 2 weeks of initiating or dose-adjusting these medications to prevent life-threatening cardiac arrhythmias and progressive renal dysfunction.

Step-by-Step Solution

1
Analyze the patient's new medication regimen and the associated mechanisms of action.
The regimen includes lisinopril (an ACE inhibitor) and spironolactone (a mineralocorticoid receptor antagonist), both of which inhibit the renin-angiotensin-aldosterone system.
Identifying the pharmacologic classes helps predict their common and severe adverse effects.
2
Determine the physiologic effects of dual renin-angiotensin-aldosterone system inhibition.
Combining an ACE inhibitor and an aldosterone antagonist significantly decreases potassium excretion in the distal nephron and alters intra-renal hemodynamics by dilating the efferent arteriole.
Understanding the synergistic effects of these medications highlights the risk for severe hyperkalemia and acute kidney injury.
3
Select the appropriate laboratory tests for early surveillance.
Serum potassium and serum creatinine must be checked within one to two weeks of initiating or up-titrating this combination.
Early detection of hyperkalemia and renal impairment prevents life-threatening arrhythmias and progressive renal failure.

Key Concept

Routine monitoring of serum potassium and renal function is mandatory when initiating or combining medications that block the renin-angiotensin-aldosterone system (such as ACE inhibitors and mineralocorticoid receptor antagonists) due to the high risk of life-threatening hyperkalemia and acute kidney injury.
Estimated Time:1m 30s
Question 1412Question →

A 64-year-old man is currently receiving mechanical ventilation in the intensive care unit following a severe traumatic brain injury. On hospital day 5, he develops a new fever of 39.2°C (102.6°F), an increased requirement for fraction of inspired oxygen (FiO2), and thick, purulent endotracheal secretions. A portable chest radiograph reveals a new left lower lobe consolidation. The patient is hemodynamically stable but exhibits signs of systemic inflammation.

Arrange the following steps in the most appropriate chronological sequence for the diagnostic workup, therapeutic management, and subsequent monitoring of this patient's suspected ventilator-associated pneumonia (VAP).

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence is to first obtain respiratory cultures, immediately follow with empiric broad-spectrum antibiotics, clinically reassess at 48 to 72 hours alongside culture results, de-escalate to targeted therapy based on those results, and continuously monitor the patient to complete a 7-day treatment course.
The management of suspected ventilator-associated pneumonia (VAP) follows a strict sequence emphasizing both timely intervention and appropriate monitoring. First, a lower respiratory tract sample must be obtained before any new antibiotics are given; early administration can rapidly sterilize cultures and obscure the diagnosis. Second, empiric therapy targeting typical nosocomial pathogens (such as MRSA and Pseudomonas aeruginosa) must be started immediately to prevent clinical deterioration. Third, a formal clinical reassessment is required at 48 to 72 hours when final microbiologic data become available. Fourth, based on these results, the broad-spectrum regimen should be de-escalated to a targeted agent to minimize resistance. Finally, the patient's response to this targeted therapy is monitored daily to ensure clinical stability, with the goal of completing a standard 7-day treatment course.

Step-by-Step Solution

1
Establish a microbiologic diagnosis prior to treatment.
Lower respiratory tract cultures and a Gram stain are obtained.
To accurately identify the pathogen and its susceptibilities, which is crucial for guiding later targeted therapy. Antibiotics given beforehand can sterilize the sample.
2
Provide immediate empiric broad-spectrum treatment.
Intravenous antibiotics covering MRSA and Pseudomonas aeruginosa are initiated.
To ensure timely coverage of severe hospital-acquired pathogens while awaiting definitive culture results, minimizing morbidity.
3
Perform a scheduled clinical and microbiologic reassessment.
The patient's clinical response and final culture results are evaluated at 48 to 72 hours.
To determine the effectiveness of the initial regimen and gather the necessary data for antimicrobial stewardship interventions.
4
Implement antimicrobial stewardship by narrowing therapy.
The antibiotic regimen is de-escalated to narrow-spectrum agents.
To minimize patient toxicity, reduce healthcare costs, and prevent the emergence of multidrug-resistant organisms and Clostridioides difficile infection.
5
Complete the treatment course and monitor for infection resolution.
The patient's clinical status is monitored daily until a standard 7-day course is completed.
To confirm that the infection has cleared while adhering to guideline-recommended shorter durations for VAP to minimize harm.

Key Concept

The optimal sequence for evaluating, treating, and monitoring ventilator-associated pneumonia incorporates prompt pre-antibiotic culturing, immediate broad-spectrum empiric therapy, and subsequent culture-guided de-escalation with a limited 7-day duration.
Question 1413Question →

A 42-year-old woman presents to the emergency department with a 2-day history of high fever, chills, and severe sore throat. She was diagnosed with hyperthyroidism due to Graves' disease 4 weeks ago and was started on methimazole and propranolol. Her temperature is 39.2∘C39.2^\circ\text{C} (102.6∘F102.6^\circ\text{F}), blood pressure is 110/70110/70 mm Hg, heart rate is 112112/min, and respiratory rate is 1818/min. Physical examination reveals marked pharyngeal erythema with tonsillar exudates but no neck asymmetry or airway compromise. Laboratory studies show:

TestResult
Hemoglobin12.4 g/dL12.4\text{ g/dL}
Platelets210,000/mm3210,000/\text{mm}^3
Leukocytes900/mm3900/\text{mm}^3
Neutrophils15%15\%
Lymphocytes80%80\%
Monocytes5%5\%

Which of the following is the most appropriate next step in the management of this patient?

Show answer & explanation

Answer: Discontinue methimazole, admit to the hospital, and initiate intravenous broad-spectrum antibiotics

Answer

Discontinue methimazole, admit to the hospital, and initiate intravenous broad-spectrum antibiotics
The correct answer identifies the need to stop the offending medication and aggressively treat the resulting immunocompromised state. This patient has developed methimazole-induced agranulocytosis, an idiosyncratic and life-threatening adverse effect of thionamides that most frequently occurs within the first 90 days of therapy. Her absolute neutrophil count (ANC) is 135/mm3135/\text{mm}^3 (900/mm3×15%900/\text{mm}^3 \times 15\%). An ANC less than 500/mm3500/\text{mm}^3 in the presence of fever defines febrile neutropenia, a medical emergency. The most appropriate next step in management is the immediate discontinuation of methimazole, hospital admission, and prompt initiation of intravenous broad-spectrum antibiotics (such as cefepime, meropenem, or piperacillin-tazobactam) to provide empiric coverage against typical pathogens, particularly *Pseudomonas aeruginosa*. Once recovered, definitive management of her Graves' disease will likely require radioactive iodine ablation or surgery.

Step-by-Step Solution

1
Calculate the Absolute Neutrophil Count (ANC).
ANC=Total Leukocytes×Percentage of Neutrophils=900×0.15=135/mm3\text{ANC} = \text{Total Leukocytes} \times \text{Percentage of Neutrophils} = 900 \times 0.15 = 135/\text{mm}^3.
To determine the severity of the neutropenia based on the complete blood count with differential.
2
Identify the clinical syndrome and its etiology.
The patient has febrile neutropenia (ANC<500/mm3\text{ANC} < 500/\text{mm}^3 with fever >38.3∘C> 38.3^\circ\text{C}), secondary to methimazole-induced agranulocytosis.
Antithyroid drugs (methimazole, propylthiouracil) carry a known risk of idiosyncratic agranulocytosis, which typically presents with sudden-onset fever and sore throat within the first 90 days of therapy.
3
Determine the appropriate management setting and interventions.
The offending agent must be stopped immediately. The patient requires inpatient admission and empiric intravenous broad-spectrum antibiotics.
Febrile neutropenia is a life-threatening emergency with a high risk of rapid progression to overwhelming sepsis if not treated aggressively.

Key Concept

Evaluation and management of antithyroid drug-induced agranulocytosis (febrile neutropenia)
Estimated Time:1m 30s
Question 1414Question →

A 22-year-old woman comes to the dermatology clinic for the management of severe nodulocystic acne. Over the past six months, she has been treated with oral doxycycline and topical benzoyl peroxide, but her condition has worsened. She has deep, painful cystic lesions on her face, back, and chest that are beginning to scar. The physician plans to initiate oral isotretinoin. She has no other medical conditions. Which of the following are essential components of this patient's treatment and monitoring plan? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: Monthly human chorionic gonadotropin testing; Baseline and periodic fasting lipid panel; Baseline and periodic liver aminotransferases

Answer

The correct components are monthly human chorionic gonadotropin testing, baseline and periodic fasting lipid panels, and baseline and periodic liver aminotransferases.
Isotretinoin is a highly effective but high-risk medication for severe nodulocystic acne. Because it is highly teratogenic, strict adherence to a pregnancy prevention program is mandatory, requiring two negative baseline pregnancy tests and monthly human chorionic gonadotropin (hCG) testing during therapy. Additionally, isotretinoin can cause significant elevations in serum triglycerides and liver aminotransferases. Therefore, a fasting lipid panel and liver function tests must be checked at baseline and monitored periodically (typically after 1-2 months) to evaluate for hypertriglyceridemia and hepatotoxicity.

Parameter / ActionClinical Rationale
Monthly hCGSevere teratogenicity (mandatory prevention program)
Fasting lipid panelRisk of hypertriglyceridemia and pancreatitis
Liver aminotransferasesRisk of hepatotoxicity
Avoid tetracyclinesPrevents pseudotumor cerebri

Step-by-Step Solution

1
Identify the new medication and its primary toxicity profile.
Isotretinoin is a systemic retinoid with significant teratogenic, metabolic, and hepatotoxic risks.
Recognizing the side effect profile is necessary to select appropriate monitoring tests.
2
Select the mandatory laboratory monitoring parameters based on the toxicity profile.
Monthly hCG testing, along with baseline and periodic lipid panels and LFTs, are strictly required.
These tests monitor for pregnancy, hypertriglyceridemia, and transaminitis, which are the most critical adverse effects.
3
Evaluate current medications for absolute contraindications and interactions.
Doxycycline must be discontinued before starting isotretinoin.
Concomitant use of isotretinoin and tetracyclines exponentially increases the risk of idiopathic intracranial hypertension.

Key Concept

Monitoring requirements for isotretinoin therapy include rigorous pregnancy testing, lipid panels, and liver function tests. Concurrent use of tetracyclines must be strictly avoided due to the compounded risk of pseudotumor cerebri.
Question 1415Question →

A 58-year-old woman is evaluated in the hospital prior to being transferred from the intensive care unit to the general medical ward. She was admitted 6 days ago for a severe exacerbation of chronic obstructive pulmonary disease. Her treatment during hospitalization has included intravenous methylprednisolone, nebulized bronchodilators, and prophylactic subcutaneous unfractionated heparin. Her respiratory status has significantly improved.

Serial laboratory studies reveal the following platelet counts:

Hospital DayPlatelet Count
Day 1 (Admission)310,000/mm³
Day 4260,000/mm³
Day 6 (Today)145,000/mm³

On physical examination today, her vital signs are within normal limits. A new, demarcated, erythematous, and exquisitely tender necrotic skin lesion is noted at a recent heparin injection site on her anterior abdomen. There is no mucosal bleeding or petechiae.

Which of the following is the most appropriate next step in the management of this patient?

Show answer & explanation

Answer: Discontinue unfractionated heparin and initiate argatroban

Answer

Discontinue unfractionated heparin and initiate argatroban
The correct management for a patient with a high clinical probability of Heparin-Induced Thrombocytopenia (HIT)—evidenced by a >50% relative drop in platelets starting 5-10 days after heparin initiation and a necrotic skin lesion at the injection site—is to immediately discontinue all heparin products and begin alternative anticoagulation with a non-heparin agent such as a direct thrombin inhibitor (e.g., argatroban).

Step-by-Step Solution

1
Analyze the patient's laboratory trends and physical exam findings.
The patient experienced a >50% drop in platelet count (from 310,000 to 145,000/mm³) occurring 5 days after starting unfractionated heparin, accompanied by an abdominal necrotic skin lesion at the injection site.
These are hallmark signs of Heparin-Induced Thrombocytopenia (HIT) type II, a severe immune-mediated adverse drug reaction.
2
Determine the necessary treatment modification based on clinical diagnosis.
All forms of heparin must be immediately discontinued.
Continuing heparin will exacerbate the antibody-mediated platelet activation, leading to severe venous or arterial thrombosis.
3
Select the appropriate alternative pharmacotherapy.
Argatroban (or another non-heparin anticoagulant) should be initiated.
Patients with HIT are in a highly prothrombotic state. A direct thrombin inhibitor like argatroban provides safe, immediate anticoagulation without cross-reacting with HIT antibodies.

Key Concept

Diagnosis and management of Heparin-Induced Thrombocytopenia (HIT) requiring immediate transition to non-heparin anticoagulation.
Question 1416Question →

During a routine health maintenance examination, a physician evaluates a patient with poorly controlled type 2 diabetes mellitus and new-onset eruptive xanthomas on the extensor surfaces. Fasting laboratory results reveal a serum triglyceride concentration of 1,340 mg/dL1,340 \text{ mg/dL}. The patient is currently managed with metformin monotherapy and lacks any history of atherosclerotic cardiovascular disease.

Please arrange the following clinical actions in the correct chronological sequence for the management and monitoring of this patient's condition over time.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct chronological sequence is to first prescribe fenofibrate to prevent pancreatitis, then recheck the lipid panel in 4 to 8 weeks, subsequently initiate statin therapy once triglycerides are <500 mg/dL<500 \text{ mg/dL}, and finally monitor for adverse effects of the combination therapy.
The management of severe hypertriglyceridemia (≥1,000 mg/dL\ge 1,000 \text{ mg/dL}) follows a strict sequence driven by competing clinical risks. The immediate danger is acute pancreatitis, dictating that fibrate therapy (e.g., fenofibrate) must be initiated first. Once the patient begins the fibrate, the physician must evaluate the therapeutic response by rechecking a fasting lipid panel in 4 to 8 weeks. When the triglyceride level safely drops below 500 mg/dL500 \text{ mg/dL}, the acute threat of pancreatitis is resolved. At this point, the patient's long-term risk of atherosclerotic cardiovascular disease (ASCVD) takes precedence. Because this patient has diabetes, a statin is strongly indicated for primary prevention. Finally, because the patient is now on combination therapy (statin plus fibrate), they are at an elevated risk for myopathy and hepatic toxicity, necessitating ongoing clinical and laboratory monitoring.

Step-by-Step Solution

1
Identify the immediate clinical threat.
The triglyceride level of 1,340 mg/dL1,340 \text{ mg/dL} places the patient at high imminent risk for acute pancreatitis.
Triglyceride levels above 500−1,000 mg/dL500-1,000 \text{ mg/dL} require immediate fibrate therapy rather than statins to prevent pancreatic inflammation.
2
Evaluate the initial treatment response.
A follow-up lipid panel is ordered 4 to 8 weeks after starting fenofibrate.
Monitoring ensures the medication is effectively lowering triglycerides below the critical 500 mg/dL500 \text{ mg/dL} threshold, establishing safety.
3
Address long-term cardiovascular risk.
Statin therapy is initiated.
Once triglycerides are <500 mg/dL<500 \text{ mg/dL}, the primary goal shifts to atherosclerotic cardiovascular disease (ASCVD) prevention, indicated for diabetic patients.
4
Monitor for adverse effects of combination therapy.
The patient is assessed for myopathy and transaminitis.
The combination of a fibrate and a statin increases the risk of muscle toxicity and liver injury, requiring careful post-initiation surveillance.

Key Concept

In patients with severe hypertriglyceridemia (≥500−1,000 mg/dL\ge 500-1,000 \text{ mg/dL}), the initial focus is preventing acute pancreatitis with fibrates; once triglycerides are successfully monitored and confirmed to be <500 mg/dL<500 \text{ mg/dL}, the focus shifts to ASCVD risk reduction with statins, followed by clinical evaluation for combined toxicity.
Question 1417Question →

Evaluate the following complex end-of-life patient presentations and pair each with its most appropriate, symptom-specific intervention.

Click a left item, then click its matching right item

Items

A 64-year-old man with multiple myeloma and acute oliguric renal failure develops diffuse allodynia and severe multifocal myoclonus while receiving continuous intravenous morphine.
A 77-year-old woman with end-stage cor pulmonale is actively dying and exhibits profound air hunger. She is opioid-naive, lacks intravenous access, and her surrogate refuses new line placements.
A 68-year-old man with metastatic gastric cancer is unresponsive in his final hours with distressing oropharyngeal secretions. He has a known history of closed-angle glaucoma.
A 52-year-old woman with leptomeningeal carcinomatosis exhibits severe, hyperactive terminal delirium that remains completely refractory to escalating doses of intravenous haloperidol.

Matches

Show answer & explanation

Answer

The correct pairings align the patient with opioid-induced neurotoxicity to fentanyl/methadone rotation, the patient with terminal dyspnea without IV access to sublingual morphine, the patient with terminal secretions and glaucoma to subcutaneous glycopyrrolate, and the patient with refractory terminal delirium to a continuous midazolam infusion.
Each vignette describes a highly specific, complex palliative care scenario requiring a tailored intervention. The correct matches prioritize patient safety, route availability, and precise pharmacological appropriateness in the setting of terminal illness and organ dysfunction.

Step-by-Step Solution

1
Analyze the underlying etiology of the refractory symptom in the context of the patient's comorbidities.
Identified critical factors: acute renal failure causing morphine metabolite accumulation, lack of IV access in severe dyspnea, closed-angle glaucoma complicating anticholinergic use, and haloperidol failure in terminal delirium.
Comorbidities and prior treatment failures strictly dictate the next pharmacological step in advanced palliative care.
2
Identify the pharmacological properties and limitations of available palliative interventions.
Determined that morphine produces neurotoxic metabolites in renal failure, scopolamine crosses the blood-brain barrier and exacerbates glaucoma, and haloperidol has a ceiling effect for profound terminal agitation.
Matching the correct drug requires understanding its pharmacokinetics, route availability, and contraindications.
3
Select the targeted palliative intervention that bypasses the identified limitation while adhering to ethical end-of-life care principles.
Selected fentanyl for renal safety, sublingual morphine for non-invasive rapid absorption, glycopyrrolate for its inability to cross the blood-brain barrier, and midazolam for proportional palliative sedation.
Ensures evidence-based, safe, and effective symptom relief in the active dying phase.

Key Concept

Advanced symptom management in palliative care requires tailoring pharmacological interventions to patient-specific pharmacokinetic alterations (e.g., organ failure), strict contraindications (e.g., glaucoma), and the principle of proportional sedation for refractory distress.
Question 1418Question →

A 68-year-old retired architect is brought to the emergency department by her husband after a transient loss of consciousness. She was sitting in a chair reading when she suddenly "blacked out." Her husband witnessed the event and reports she was unresponsive for approximately 20 seconds. She had no preceding palpitations, chest pain, diaphoresis, or nausea. There was no limb jerking or urinary incontinence, and she returned to her baseline mental status immediately upon awakening. Her medical history includes hypertension and hyperlipidemia. Blood pressure is 138/82 mmHg, heart rate is 64/min, and respiratory rate is 14/min. Orthostatic vital signs show no significant changes. Physical examination reveals clear lungs and a 2/6 late-peaking systolic murmur at the right upper sternal border. Neurologic examination is nonfocal. An electrocardiogram demonstrates normal sinus rhythm with left axis deviation and a new right bundle branch block (bifascicular block). Basic metabolic panel and complete blood count are within normal limits. Which of the following diagnostic studies are indicated as the most appropriate concurrent initial steps in this patient's evaluation? (Select exactly 2)

Select all that apply

Show answer & explanation

Answer: Transthoracic echocardiography; Continuous electrocardiographic monitoring

Answer

The most appropriate initial concurrent diagnostic steps are transthoracic echocardiography and continuous electrocardiographic monitoring.
This patient exhibits multiple "red flag" features for cardiogenic syncope: sudden onset without a prodrome while in a seated position, a new bifascicular block on ECG, and a physical examination finding consistent with aortic stenosis. The most appropriate initial step in test sequencing is a concurrent cardiac workup. Transthoracic echocardiography is required to define the severity of the suspected structural heart disease, and continuous electrocardiographic monitoring is required to capture potential intermittent high-grade atrioventricular blocks or ventricular tachyarrhythmias.

Step-by-Step Solution

1
Analyze the clinical characteristics of the syncopal event.
The event occurred suddenly while seated, without prodrome, and was followed by rapid and complete recovery.
These features strongly suggest a cardiogenic etiology (arrhythmia or structural) rather than a reflex (vasovagal) or neurologic cause.
2
Evaluate the physical examination and electrocardiogram (ECG) data.
Examination shows a late-peaking systolic murmur, and the ECG reveals a new bifascicular block.
The murmur raises suspicion for aortic stenosis (a structural cause of syncope), while the bifascicular block indicates advanced conduction system disease, putting the patient at risk for high-grade AV block.
3
Determine the optimal diagnostic testing sequence.
Select non-invasive cardiac structural and electrical assessments to be performed concurrently.
In high-risk syncope, life-threatening cardiac causes must be immediately evaluated before any consideration of outpatient reflex testing or neuroimaging.

Key Concept

Patients with syncope presenting with high-risk features (lack of prodrome, onset while seated/supine, structural murmurs, or ECG conduction blocks) require concurrent immediate evaluation for structural heart disease via echocardiography and arrhythmic causes via continuous electrocardiographic monitoring.
Question 1419Question →

A 42-year-old woman is evaluated in the surgical intensive care unit on postoperative day 3 following an uncomplicated laparoscopic Roux-en-Y gastric bypass for severe obesity. Over the past 2 hours, she has developed severe, unremitting epigastric pain, severe restlessness, and shortness of breath. Her temperature is 38.8°C (101.8°F), blood pressure is 82/48 mm Hg, heart rate is 135/min, and respiratory rate is 26/min. Pulse oximetry shows 92% on room air. The patient appears diaphoretic, anxious, and acutely ill. Abdominal examination reveals diffuse tenderness, marked involuntary guarding, and rebound tenderness predominantly in the epigastrium. Bowel sounds are absent. Urine output has been 10 mL over the last 2 hours. Laboratory studies show a leukocyte count of 19,000/mm³ with 15% band forms and a serum lactate level of 4.2 mmol/L. She is given a rapid intravenous infusion of 2 L of isotonic crystalloid, after which her blood pressure is 86/52 mm Hg. Which of the following is the most appropriate next step in management?

Show answer & explanation

Answer: Emergent surgical exploration

Answer

Emergent surgical exploration
The correct approach is emergent surgical exploration. This patient exhibits classic signs of a postoperative anastomotic leak (specifically, the gastrojejunostomy in Roux-en-Y gastric bypass), characterized by severe tachycardia, fever, and tachypnea on postoperative day 2 or 3. Furthermore, she has progressed to septic shock (hypotension unresponsive to fluid resuscitation, lactic acidosis) and diffuse peritonitis (rigid abdomen, rebound tenderness). The fundamental principle of surgical critical care dictates that a hemodynamically unstable patient with an acute surgical abdomen requires immediate operative intervention for source control. Delaying surgery for any form of diagnostic imaging in this state drastically increases mortality.

Step-by-Step Solution

1
Identify the primary clinical syndrome.
The patient is on postoperative day 3 from a gastric bypass and exhibits sudden-onset severe abdominal pain, high fever, and marked tachycardia (135/min).
Tachycardia is often the earliest and most sensitive sign of an anastomotic leak in post-bariatric surgery patients.
2
Assess the patient's hemodynamic status and physical examination findings.
The patient has refractory hypotension (86/52 mm Hg despite 2 L of fluids), elevated lactate (4.2 mmol/L), oliguria, and diffuse peritonitis (rebound, guarding).
These findings confirm the presence of uncontained intra-abdominal sepsis resulting in septic shock.
3
Determine the safest and most definitive management pathway.
The correct action is immediate transfer to the operating room for exploratory laparoscopy or laparotomy.
Diagnostic imaging is contraindicated in hemodynamically unstable patients with peritonitis because it unacceptably delays definitive surgical source control.

Key Concept

In patients with suspected postoperative anastomotic leaks who present with diffuse peritonitis and hemodynamic instability, emergent surgical exploration is required; diagnostic imaging should be bypassed to avoid delaying life-saving source control.
Estimated Time:1m 30s
Question 1420Question →

A 54-year-old woman with severe, seropositive rheumatoid arthritis is evaluated in the rheumatology clinic. She continues to experience active synovitis in multiple metacarpophalangeal and proximal interphalangeal joints despite a 6-month trial of optimized methotrexate and a subsequent 4-month trial of etanercept. The physician decides to initiate intravenous tocilizumab. Her medical history is otherwise unremarkable. Baseline screening for latent tuberculosis and viral hepatitis is negative. Which of the following laboratory evaluations are required as part of the specific baseline and ongoing monitoring for this pharmacotherapy? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: Assessment of absolute neutrophil count, platelet count, and liver transaminases; Measurement of a fasting lipid panel 4 to 8 weeks following treatment initiation

Answer

The necessary monitoring parameters are the assessment of absolute neutrophil count, platelet count, and liver transaminases, as well as the measurement of a fasting lipid panel 4 to 8 weeks following treatment initiation.
Tocilizumab is a monoclonal antibody directed against the interleukin-6 (IL-6) receptor. IL-6 plays a significant role in lipid metabolism, and its inhibition frequently leads to elevated total cholesterol, LDL, and triglycerides. Therefore, a fasting lipid panel is required 4 to 8 weeks after starting therapy and periodically thereafter to determine if lipid-lowering therapy is necessary. Furthermore, tocilizumab can cause dose-dependent neutropenia, thrombocytopenia, and elevated hepatic transaminases. Complete blood counts (to assess absolute neutrophil count and platelets) and liver function tests must be monitored at baseline and routinely (e.g., every 4 to 8 weeks) during ongoing therapy to safely guide dosing.

Step-by-Step Solution

1
Identify the initiated medication and its mechanism of action.
The medication is tocilizumab, which is an interleukin-6 (IL-6) receptor antagonist.
Understanding the pharmacologic mechanism is required to predict adverse effects and required monitoring.
2
Recall the unique adverse effect profile associated with IL-6 inhibition.
IL-6 inhibition is uniquely associated with dyslipidemia, neutropenia, thrombocytopenia, and hepatotoxicity.
Targeted biologic therapies have specific, mechanism-based adverse event profiles distinct from conventional immunosuppressants.
3
Select the laboratory tests that directly monitor for these specific adverse effects.
A fasting lipid panel, complete blood count (for ANC and platelets), and liver function tests are necessary.
Guideline-concordant care requires vigilant surveillance of these specific parameters to ensure patient safety and guide potential dose adjustments or statin initiation.

Key Concept

Monitoring parameters for interleukin-6 (IL-6) receptor antagonists (e.g., tocilizumab) include baseline and ongoing complete blood counts, liver transaminases, and fasting lipid panels.
PreviousPage 71 / 104Next